Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CRO Inspection Fall-Out: Semler's Clients Have To Repeat Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Data integrity spotlight expands beyond cGMP as FDA finds Semler manipulated study subject samples in bioequivalence studies conducted at its Bangalore facility.


Related Content

WHO Tackles Submission Of Insufficient Or False Data By Pharma
Foreign Regulators Rap More Indian Firms Over Data Integrity
Watson’s Bupropion XL Undone By Outlier Patient, Bankrupt CRO
Cetero Fallout: Five Years Of Potentially False Data Creates Three Tough Options For Sponsors


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst